Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Pharma Roundup: ImClone a Done Deal, FDA Approvals Up, and More
- ImClone leaving the headlines at last, perhaps; FDA beats last year's approval rate, despite a string of delays; a good biotech merger for a bad economy. by John Maas
- Blog posts 2008-11-21
Additional Resources
- Archemix and Takeda to Enter into Collaboration for Discovery and Development of Aptamer Therapeutics
- CAMBRIDGE, Mass. & OSAKA, Japan -- Archemix Corp. ("Archemix") and Takeda Pharmaceutical Company Limited ("Takeda") announced today that both parties have signed a multi-year, three target agreement that focuses on the discovery, development and commercialization of first-in-class aptamer-based therapeutics. Under the agreement, Archemix will receive an upfront payment of...
- Research articles 2007-06-11
- Nitromed Is Archemix's Back Door onto the Stock Market
- Derek Lowe submits: Nitromed NTMD has been in trouble for several years now. They're a perfect example of a dog that caught a car: a company that was demolished by actually getting its drug on the market. No one wanted to pay for it, though, and after all that...
- External links 2008-11-21
- Cambridge, Mass., Biotech Drug Firm Lands $50 Million in Venture Funding.
- By Beth Healy, The Boston Globe Knight Ridder/Tribune Business News Apr. 6--Archemix Corp., a private drug-development start-up in Cambridge, has landed $50 million in venture capital, providing fresh evidence that investors and venture firms are eager to fund hot biotech companies. ...
- Research articles 2004-04-06
- Targacept
- Targacept, Winston-Salem, North Carolina, a central nervous system-focused biopharmaceuticals company, has announced the addition of Errol De Souza to its board of directors. De Souza is currently president and CEO of Archemix, a biopharmaceutical company developing aptamer therapeutics, Before joining Archemix, De Souza was president and CEO of Synaptic Pharmaceutical....
- Research articles 2004-02-16
- Archemix Receives $2 Million Credit Facility From Comerica Bank
- Business Editors/Health & Medical Writers
- Research articles 2001-11-27
- Archemix and Merck KGaA Sign Strategic Alliance
- Collaboration to Focus Primarily on Cancer Therapeutics Using Novel Aptamer Technology
- Research articles 2007-06-11
- NitroMed Courted
- Derek Lowe submits: Remember that NitroMed NTMD/Archemix deal that I mentioned briefly back in November? Well, it's not going so smoothly. One of the largest NitroMed shareholders, Deerfield Management, objected to the whole idea, and proposed buying the company itself. Last week the company adjourned its shareholder meeting until...
- External links 2009-01-21
- Pharma Roundup: Lilly and Prasugrel, Roche and Genentech, and More
- Prasugrel's FDA approval looks closer -- Prasugrel, the blood thinner on which Lilly is pinning so much hope, got a boost in a newly-published FDA document stating that "the Division recommends approval of prasugrel." The briefing is meant to sway the outside committee that will convene next week to advise...
- Blog posts 2009-01-30
- << Previous
- page 1 of 1
- Next >>
